FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC) Meeting Abstract
| Authors: | Oliveira, M.; Saura, C.; Gonzalez Martin, A.; Andersen, J. C.; Fisher, J. G.; Calvo, I.; Ciruelos, E.; Gil, M.; de la Pena, L.; Llobet-Canela, M.; Choi, Y.; Jia, S. D.; Yalamanchili, S.; Singel, S. M.; Patel, P. H.; Baselga, J.; Isakoff, S. J. |
| Abstract Title: | FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904671 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.tps1112 |
| Notes: | Meeting Abstract: TPS1112 -- Source: Wos |
